BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv 2020;4:6039-50. [PMID: 33284946 DOI: 10.1182/bloodadvances.2020003334] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Nishimura MF, Nishimura Y, Nishikori A, Maekawa Y, Maehama K, Yoshino T, Sato Y. Clinical and Pathological Characteristics of Hyaline-Vascular Type Unicentric Castleman Disease: A 20-Year Retrospective Analysis. Diagnostics (Basel) 2021;11:2008. [PMID: 34829355 DOI: 10.3390/diagnostics11112008] [Reference Citation Analysis]
2 Lust H, Gong S, Remiker A, Rossoff J. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series. Pediatr Blood Cancer 2021;68:e29261. [PMID: 34302703 DOI: 10.1002/pbc.29261] [Reference Citation Analysis]
3 Yu Y, Wang T, Yang K, Zhang X, Yu SCH, Luo J, Yang B, Wang Y, Ma Y, Gao P, Jiao L. Timing and Outcomes of Intracranial Stenting in the Post-SAMMPRIS Era: A Systematic Review. Front Neurol 2021;12:637632. [PMID: 33613442 DOI: 10.3389/fneur.2021.637632] [Reference Citation Analysis]
4 Zhai HY, Zhu XY, Zhou GM, Zhu L, Guo DD, Zhang H. Unicentric Castleman disease was misdiagnosed as pancreatic mass: A case report. World J Clin Cases 2022; 10(4): 1278-1285 [DOI: 10.12998/wjcc.v10.i4.1278] [Reference Citation Analysis]
5 Pierson SK, Khor JS, Ziglar J, Liu A, Floess K, NaPier E, Gorzewski AM, Tamakloe MA, Powers V, Akhter F, Haljasmaa E, Jayanthan R, Rubenstein A, Repasky M, Elenitoba-Johnson K, Ruth J, Jacobs B, Streetly M, Angenendt L, Patier JL, Ferrero S, Zinzani PL, Terriou L, Casper C, Jaffe E, Hoffmann C, Oksenhendler E, Fosså A, Srkalovic G, Chadburn A, Uldrick TS, Lim M, van Rhee F, Fajgenbaum DC. ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Rep Med 2020;1:100158. [PMID: 33377129 DOI: 10.1016/j.xcrm.2020.100158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang T, Chen X, Chen W, Shi L, Liu J. A retrospective study of 44 patients with head and neck Castleman's disease. Eur Arch Otorhinolaryngol 2021. [PMID: 34480599 DOI: 10.1007/s00405-021-07065-0] [Reference Citation Analysis]
7 Fan HS, Yan WW, Xu JY, Liu JH, Du CX, Sui WW, Deng SH, Liu W, Yi SH, Huang WY, Xu Y, Zhao YZ, Qiu LG, Zou DH, An G. [Analysis of the clinical characteristics and prognosis of 20 patients with multicenter Castleman disease]. Zhonghua Xue Ye Xue Za Zhi 2021;42:510-3. [PMID: 34384159 DOI: 10.3760/cma.j.issn.0253-2727.2021.06.012] [Reference Citation Analysis]
8 Potere N, Batticciotto A, Vecchié A, Porreca E, Cappelli A, Abbate A, Dentali F, Bonaventura A. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol 2021;17:601-18. [PMID: 33874829 DOI: 10.1080/1744666X.2021.1919086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zhu X, Chen S, Fang F, Jia Y, Zhang K. An unusual cause of ascites: Castleman disease. BMC Gastroenterol 2021;21. [DOI: 10.1186/s12876-021-02050-7] [Reference Citation Analysis]
10 Mohan M, Meek JC, Meek ME, Broadwater R, Alapat D, van Rhee F. Combinatorial treatment for unresectable unicentric Castleman disease. Eur J Haematol 2021. [PMID: 34242421 DOI: 10.1111/ejh.13685] [Reference Citation Analysis]